Literature DB >> 17088984

CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion.

Yigong Fu1, Radoslaw Zagozdzon, Ron Avraham, Hava Karsenty Avraham.   

Abstract

Among the most important signaling pathways operating in pancreatic cancer cells are those resulting from mutations in the Ras oncogene or from overexpression of ErbB-2 and associated Src-family kinases. In this study, we aimed to characterize CHK expression and function in pancreatic cancer. Our data demonstrated CHK expression in human pancreatic cancer tissues, and also showed that CHK associated with ErbB-2 via its SH2 domain in human PANC-1 pancreatic cancer cells. PANC-1 cells were found to express both Src kinase and Lyn kinase, although the expression of Lyn kinase was more abundant. Furthermore, CHK downregulated Lyn kinase activity and significantly inhibited the in vitro growth and invasion of PANC-1 cells upon EGF stimulation. These results indicate that CHK is a negative regulator of ErbB-2 and Lyn kinase signaling in pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088984

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.

Authors:  B Elsberger; R Fullerton; S Zino; F Jordan; T J Mitchell; V G Brunton; E A Mallon; P G Shiels; J Edwards
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

Review 2.  The role of Src in solid tumors.

Authors:  Deric L Wheeler; Mari Iida; Emily F Dunn
Journal:  Oncologist       Date:  2009-07-06

3.  Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.

Authors:  Hui Guan; Zhichao Zhou; Gary E Gallick; Shu-Fang Jia; Jaime Morales; Anil K Sood; Seth J Corey; Eugenie S Kleinerman
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

4.  Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.

Authors:  Jan Skoda; Marketa Hermanova; Tomas Loja; Pavel Nemec; Jakub Neradil; Petr Karasek; Renata Veselska
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

5.  mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival.

Authors:  Ana-Barbara García-García; M Carmen Gómez-Mateo; Rebeca Hilario; Pilar Rentero-Garrido; Alvaro Martínez-Domenech; Veronica Gonzalez-Albert; Andres Cervantes; Pablo Marín-Garcia; Felipe Javier Chaves; Antonio Ferrández-Izquierdo; Luis Sabater
Journal:  Oncotarget       Date:  2017-08-03

6.  ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia.

Authors:  Johnvesly Basappa; Mevlut Citir; Qian Zhang; Hong Y Wang; Xiaobin Liu; Olga Melnikov; Hafiz Yahya; Frank Stein; Rainer Muller; Alexis Traynor-Kaplan; Carsten Schultz; Mariusz A Wasik; Andrzej Ptasznik
Journal:  Heliyon       Date:  2020-05-07

Review 7.  Mitochondrial Kinases and the Role of Mitochondrial Protein Phosphorylation in Health and Disease.

Authors:  Veronika Kotrasová; Barbora Keresztesová; Gabriela Ondrovičová; Jacob A Bauer; Henrieta Havalová; Vladimír Pevala; Eva Kutejová; Nina Kunová
Journal:  Life (Basel)       Date:  2021-01-23

Review 8.  Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia.

Authors:  Justin F Creeden; Khaled Alganem; Ali S Imami; Nicholas D Henkel; F Charles Brunicardi; Shi-He Liu; Rammohan Shukla; Tushar Tomar; Faris Naji; Robert E McCullumsmith
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

Review 9.  Src as the link between inflammation and cancer.

Authors:  Sandy T Liu; Hung Pham; Stephen J Pandol; Andrzej Ptasznik
Journal:  Front Physiol       Date:  2014-01-16       Impact factor: 4.566

10.  Identification of hub genes correlated with the pathogenesis and prognosis in Pancreatic adenocarcinoma on bioinformatics methods.

Authors:  Lan-Er Shi; Xin Shang; Ke-Chao Nie; Zhi-Qin Lin; Miao Wang; Yin-Ying Huang; Zhang-Zhi Zhu
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.